Logo Image
|Articles|March 9, 2015

ACRO Holds Initial Meeting of CRO Forum, Begins Two-Way Dialogue with Transcelerate

March 9, 2015 – WASHINGTON, DCThe Association of Clinical Research Organizations, whose members account for approximately two-thirds of contract clinical development services, held the inaugural meeting of the previously announced CRO Forum in Washington, DC. The Forum was established in October 2014 as the primary vehicle for interaction between the CRO industry and TransCelerate BioPharma Inc.

The Forum elected as its first Chairman Dr. Alan Metz, Senior Vice President and Managing Director, Strategic Partnerships, at Quintiles. As Vice Chair, the Forum elected Amy Kissam, Executive Director, Global Operational Management, at INC Research.

ACRO and TransCelerate have mutually agreed to initially establish liaison relationships between four TransCelerate workstreams: risk-based monitoring; shared site qualification and training; common protocol template; and quality management system. The Forum selected senior subject matter experts to serve as liaisons to each of these workstreams. The liaisons will be supported by working groups consisting of subject matter experts from across the Forum membership.

“With the ever-increasing role CROs are playing across the drug development spectrum, and the innovation we are bringing to the process, we look forward to entering a meaningful dialogue with TransCelerate,” said ACRO Chairman Jamie Macdonald, CEO of INC Research. “As the relationship progresses, we anticipate providing CRO industry input into additional workstreams as well as suggesting possible new workstreams for TransCelerate’s consideration.”

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more